Protocol to generate, purify, and analyze antibody-oligonucleotide ...
Dec 20, 2024 · Antibody-oligonucleotide conjugates (AOCs) are a fast-expanding modality for targeted delivery of therapeutic oligonucleotides to tissues. Here, we present a protocol to generate, purify, and analyze AOCs from off-the-shelf antibodies.
Preparation of single- and double-oligonucleotide antibody conjugates ...
Jan 29, 2020 · In this study, we combined a non-site-directed antibody conjugation technique using copper-free click chemistry with ion-exchange chromatography to obtain purified single and double...
Antibody-Oligonucleotide Conjugates: A Twist to Antibody …
Antibody–oligonucleotide conjugates (AOCs) combine the high precision of siRNA and ASOs with the deliverability of antibodies, thus synergizing the advantages of both technologies.
Self-Assembled Antibody-Oligonucleotide Conjugates for …
Sep 26, 2024 · Antibody-oligonucleotide conjugate (AOC) affords preferential cell targeting and enhanced cellular uptake of antisense oligonucleotide (ASO). Here, we have developed a modular AOC (MAOC) approach based on accurate self-assembly of separately prepared antibody and …
Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug ... - PubMed
Feb 18, 2021 · A summary of the key technological advancements in the preparation of antibody-oligonucleotide conjugates (AOCs) and the distinct advantages and disadvantages of AOCs as novel therapeutics are presented.
Antibody–Oligonucleotide Conjugates as Therapeutic, Imaging, …
Jul 24, 2019 · Antibody–oligonucleotide conjugates (AOCs) are a novel class of synthetic chimeric biomolecules that has been continually gaining traction in different fields of modern biotechnology.
Its AOC 1001 uses an anti body to carry an siRNA payload to muscle cells, for a rare muscle disease. If successful, this approach stands to broaden the reach of oligonucleotides, a modality...
Non-specific interactions of antibody-oligonucleotide conjugates …
Mar 15, 2021 · Our results indicate that conjugation of single strand oligonucleotides to proteins induce consistent non-specific interactions with cell surfaces while double strand oligonucleotides have little...
Antibody–oligonucleotide conjugates enter the clinic - Nature
Dec 13, 2021 · Avidity Biosciences has advanced a first antibody–oligonucleotide conjugate (AOC) into a phase I trial. Its AOC 1001 uses an antibody to carry an siRNA payload to muscle cells, for a rare...
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials
Aug 25, 2023 · Tallac's immunotherapy candidate pipeline stems from the company's novel Toll-like receptor agonist antibody conjugate (TRAAC) platform, to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration.
- Some results have been removed